Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space

You may also be interested in...



India and China Could Be On The Brink Of A Biosimilars Takeoff, Says One Biotech CEO

SINGAPORE - Asia's giants - India and China - could see a Big Bang-like explosion of biotech- and biosimilar-focused start-ups given the right conditions over the next decade, including an infusion of capital from the West, according to the head of an Indian biopharmaceutical firm

Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics

MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC074401

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel